Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
67.96
-0.21 (-0.31%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Employees
Tarsus Pharmaceuticals had 370 employees as of December 31, 2025. The number of employees increased by 47 or 14.55% compared to the previous year.
Employees
370
Change (1Y)
47
Growth (1Y)
14.55%
Revenue / Employee
$1,219,892
Profits / Employee
-$179,508
Market Cap
2.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 370 | 47 | 14.55% |
| Dec 31, 2024 | 323 | 79 | 32.38% |
| Dec 31, 2023 | 244 | 157 | 180.46% |
| Dec 31, 2022 | 87 | 41 | 89.13% |
| Dec 31, 2021 | 46 | 26 | 130.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Viridian Therapeutics | 252 |
| Vera Therapeutics | 249 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 182 |
TARS News
- 4 days ago - Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential - Seeking Alpha
- 19 days ago - Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors - GlobeNewsWire
- 25 days ago - Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 - GlobeNewsWire
- 5 weeks ago - Allspring Emerging Growth Fund Q4 2025 Performance Review - Seeking Alpha
- 4 months ago - Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 - Seeking Alpha